Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 08:29, 18 September 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Lentinan

Clinical data
Other names	(2S,3R,4S,5S,6R)-2-oxymethyl]oxan-4-yl]oxyoxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-oxymethyl]oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
AHFS/Drugs.com	International Drug Names
ATC code	L03AX01 (WHO)
Identifiers
IUPAC name β-D-glucopyranosyl-(1→6)--β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)β-D-glucopyranosyl-(1→3)]-β-D-glucopyranose
CAS Number	37339-90-5
PubChem CID	37723
KEGG	D01695
CompTox Dashboard (EPA)	DTXSID30190781
Chemical and physical data
Formula	C42H72O36
Molar mass	1152.99948 g/mol g·mol
(verify)

Lentinan is a beta-glucan with a glycosidic β-1,3:β-1,6 linkage. It is an anti-tumor polysaccharide from the shiitake (Lentinula edodes) mushroom. Lentinan is a polysaccharide that has a molecular weight of approximately 500,000 Da. The Japanese pharmaceutical company Ajinomoto developed Lentinan, which is an intravenously administered anti-cancer agent.

Lentinan is one of the host-mediated anti-cancer drugs which has been shown to affect host defense immune systems.

Research into the effects of Lentinan

Lentinex is a formulation featuring lentinan and is approved for use in the EU. An in vitro experiment showed lentinan stimulated production of white blood cells in the human cell line U937. A pharmacological blend (MC-S) of lentinan, PSK, Ganoderma lucidum and Astragalus propinquus has also been shown to stimulate white blood cell production in vitro.

An in vivo experiment on mice, revealed lentinan is orally active (since clinical use of the drug is administered through an IV).

Limited clinical studies of cancer patients have associated lentinan with a higher survival rate, higher quality of life, and lower re-occurrence of cancer.

See also

• Medicinal mushrooms
• Shiitake
• Smith JE, Rowan NJ, Sullivan R Medicinal Mushrooms: Their Therapeutic Properties and Current Medical Usage with Special Emphasis on Cancer Treatments Cancer Research UK, 2001
• Memorial Sloan-Kettering Cancer Center's page for Lentinan.

References

1. ^ Cancer Guide Includes many abstracts
2. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061.{{cite journal}}: CS1 maint: multiple names: authors list (link)
3. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061.{{cite journal}}: CS1 maint: multiple names: authors list (link)
4. Sia GM, Candlish JK. (1999). "Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line". Phytother Res. 13 (2): 133–7. doi:10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O. PMID 10190187. {{cite journal}}: Unknown parameter |month= ignored (help)
5. Clark D, Adams M. (2007). "Using commercial nutraceutical mixes as immune stimulants: an in vitro proliferation study using Metabolic Cell-Support on non-stimulated human lymphocytes". Austr. J. Med. Herbal. 19: 108–111.
6. Ng ML, Yap AT. (2002). "Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes)". J Altern Complement Med. 8 (5). National University of Singapore: 581–9. doi:10.1089/107555302320825093. PMID 12470439. {{cite journal}}: Unknown parameter |month= ignored (help)
7. Yang P, Liang M, Zhang Y, Shen B. (2008). "Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC". Adv Ther. 25 (8): 787–94. doi:10.1007/s12325-008-0079-x. PMID 18670743. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
8. Nimura H, Mitsumori N, Takahashi N, (2006). "". Gan to Kagaku Ryoho. 33 (1): 106–9. PMID 16897983. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
9. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061. {{cite journal}}: Cite has empty unknown parameter: |month= (help)CS1 maint: multiple names: authors list (link)
10. Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2009). "Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer". Anticancer Res. 29 (7): 2739–45. PMID 19596954. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
11. Hazama S, Watanabe S, Ohashi M; et al. (2009). "Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer". Anticancer Res. 29 (7): 2611–7. PMID 19596936. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
12. Kataoka H, Shimura T, Mizoshita T; et al. (2009). "Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life". Hepatogastroenterology. 56 (90): 547–50. PMID 19579640. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
13. Isoda N, Eguchi Y, Nukaya H; et al. (2009). "Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma". Hepatogastroenterology. 56 (90): 437–41. PMID 19579616. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
14. Shimizu K, Watanabe S, Watanabe S; et al. (2009). "Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer". Hepatogastroenterology. 56 (89): 240–4. PMID 19453066. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

External links

• Lentinan effects (antitumor and others)

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Polysaccharides
• Immunostimulants
• Antineoplastic and immunomodulating drug stubs